CP CRANBURY PHARMACEUTICALS
Dead / Abandoned — Abandoned — no statement of use filed (as of 25 Dec 2023)
What this means for you
This application is over — abandoned 25 Dec 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88418271
- Mark type
- Design + words
- Filed
- 07 May 2019
- Published for opposition
- 29 Sept 2020
- Abandoned
- 25 Dec 2023
- Attorney of record
- CATHY KODROFF
Goods and services
- Class 005 — Pharmaceuticals: Prescription and non-prescription pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation; dietary supplements; nutritional supplements; vitamins; nutritional supplements in the nature of nutriceuticals for use in treating nutritional deficiencies and as dietary supplements
Owner
- CRANBURY PHARMACEUTICALS, Monmouth Junction, NJ, US
- CRANBURY PHARMACEUTICALS, Monmouth Junction, NJ, US
Prosecution history
- 26 Dec 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 25 Dec 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 18 May 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 May 2023 — SOU EXTENSION 5 GRANTED
- 12 May 2023 — SOU EXTENSION 5 FILED
- 12 May 2023 — SOU TEAS EXTENSION RECEIVED
- 05 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Nov 2022 — SOU EXTENSION 4 GRANTED
- 03 Nov 2022 — SOU EXTENSION 4 FILED
- 03 Nov 2022 — SOU TEAS EXTENSION RECEIVED
- 29 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Apr 2022 — SOU EXTENSION 3 GRANTED
- 27 Apr 2022 — SOU EXTENSION 3 FILED
- 27 Apr 2022 — SOU TEAS EXTENSION RECEIVED
- 25 Nov 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED